Provide feedbackProvide feedback

Home :: Psychiatry :: Psychiatry Conferences :: APA 2007 Annual Meeting - Insomnia track

American Psychiatric Association 2007 Annual Meeting, May 19-24

APA 2007 Annual Meeting - Insomnia track

May 19-24, 2007San Diego, CA
VerusMed is an independent news organization and is not affiliated with the American Psychiatric Association 2007 Annual Meeting, May 19-24

Ramelteon not associated with impairments in middle-of-the-night balance, mobility, memory performance among older adults with primary insomnia, data find

Wednesday, December 12, 2007 | Comments

Among older adults with primary insomnia, ramelteon may not be associated with impaired balance, mobility, or memory performance during middle-of-the-night awakenings, whereas zolpidem appears to significantly influence all 3 of these measures, new data suggest.

The double-blind, 3-way crossover study included 33 adults ...[more] Locked

Patients accurately self-identify middle-of-the-night insomnia; zolpidem improves insomnia in these patients, study data show

Wednesday, December 12, 2007 | Comments

Adult patients are capable of self-identifying their middle-of-the-night (MOTN) insomnia with great enough accuracy that subject sleep diaries can be used as diagnostic tools, study results indicate.

MOTN insomnia may occur in up to 20% of the U.S. population, according to the ...[more] Locked

No evidence of dependence with zolpidem CR during long-term treatment, findings show

Wednesday, December 12, 2007 | Comments

Among adults with chronic primary insomnia, long-term, as-needed use of zolpidem extended-release (zolpidem CR) 12.5 mg tablets does not seem to be associated with the development of tolerance or rebound insomnia, study findings demonstrate.

As part of the double-blind study, researchers randomized 1,025 adults aged 18 to ...[more] Locked

Doxepin effective, well tolerated in treatment of insomnia, study data show

Wednesday, December 12, 2007 | Comments

Treatment with doxepin appears to induce significant improvement in insomnia symptoms through approximately 1 month, according to study results.

Researchers conducted a double-blind study in which 221 patients with insomnia were randomized to receive nightly doses of doxepin 3 mg, doxepin 6 mg, or placebo for 35 days. ...[more] Locked

Ramelteon safe, effective in treatment of insomnia among women in multiple clinical trials

Wednesday, December 12, 2007 | Comments

Ramelteon appears to effectively reduce latency to persistent sleep (LPS) among women with chronic insomnia without major side effects, new data reveal.

Researchers conducted 2 separate post-hoc analyses on data from a total of 250 women in 2 double-blind, placebo-controlled trials of ramelteon. The first trial was a ...[more] Locked

Cognitive behavioral therapy, pharmacologic therapy can effectively manage patients with insomnia, expert panel agrees

Wednesday, December 12, 2007 | Comments

Insomnia can be treated effectively using pharmacologic therapy, cognitive behavioral therapy, or a combination of the 2 strategies, according to a panel of experts.

A variety of drugs are commonly prescribed to treat insomnia, many of which are not approved by the Food and Drug ...[more] Locked

Zolpidem CR effective for long-term use on as-needed basis among individuals with primary insomnia

Wednesday, December 12, 2007 | Comments

Zolpidem extended-release (zolpidem CR) appears to be an effective long-term treatment for chronic primary insomnia when taken on an as-needed basis, Phase IIIb data suggest.

In the double-blind study, researchers randomized 1,025 adults with chronic primary insomnia to take zolpidem CR 12.5 mg or placebo on an as-needed ...[more] Locked

Ramelteon significantly reduces latency to persistent sleep in adults with chronic primary insomnia, severe sleep-initiation difficulty, data indicate

Wednesday, December 12, 2007 | Comments

Among adults with chronic primary insomnia and severe sleep-initiation difficulty, ramelteon 8 mg significantly reduces latency to persistent sleep (LPS), according to a post hoc analysis.

The original Phase III trial evaluated the safety and efficacy of ramelteon 8 mg versus placebo in 405 adults with chronic primary ...[more] Locked

NG2-73 reduces latency to persistent sleep in model of transient insomnia, Phase II data show

Wednesday, December 12, 2007 | Comments

NG2-73, an investigational gamma aminobutyric acid-a (GABAa) partial agonist, appears to significantly reduce latency to persistent sleep (LPS) in a model of transient insomnia, findings from a Phase II study conducted in healthy volunteers suggest.

The double-blind, multicenter study included 369 volunteers aged 24 to 63 ...[more] Locked

Benzodiazepine dependence common among community-dwelling seniors; DSM-IV criteria may underestimate prevalence, researchers report

Wednesday, December 12, 2007 | Comments

Nearly half of all community-dwelling seniors who have a prescription for a benzodiazepine may be dependent, although few meet DSM-IV criteria for dependence, suggesting that these criteria may underestimate the true prevalence of benzodiazepine dependence among this population, new findings reveal.

Researchers in Quebec ...[more] Locked

Researchers outline strategies to improve recognition, diagnosis, treatment of insomnia

Wednesday, December 12, 2007 | Comments

Although insomnia is estimated to affect 40 million to 70 million Americans, it remains underrecognized, underdiagnosed, and undertreated, according to a panel of experts.

For physicians, the process of recognizing and diagnosing insomnia is complicated by a lack of patient awareness. People with insomnia often fail to ...[more] Locked

Adding eszopiclone to existing monotherapy may improve outcomes in patients with insomnia, comorbid MDD, GAD, researchers report

Wednesday, December 12, 2007 | Comments

Combination therapy that includes eszopiclone appears to elicit greater improvements in measures of depression among patients with insomnia and comorbid major depressive disorder or generalized anxiety disorder as compared with fluoxetine or escitalopram monotherapy, according to data from 2 studies.

"MDD and GAD can ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos